Home › Funds › Lion Point Capital, LP › JANX

Lion Point Capital, LP position in JANX

JANUX THERAPEUTICS INC · Health Care

Lion Point Capital, LP reported holding 19,000 shares of JANX (JANUX THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$292K, representing 1.40% of its reported portfolio and ranking #26 among its reported holdings. Lion Point Capital, LP has disclosed JANX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)19.00K sh
Reported value held$291.84K
Portfolio Weight1.40%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's JANX position evolved

Lion Point Capital, LP first disclosed a stake in JANX in Q4 2025 at 19,000 shares (US$262K). The position peaked in Q2 2026 at 19,000 shares, worth US$292K. Across 3 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 19,000 shares valued at US$292K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 19.00K $262.20K New
Q1 2026 19.00K $264.10K Hold
Q2 2026 19.00K $291.84K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JANX and 13F data

JANX (JANUX THERAPEUTICS INC) is a Health Care company. 28 other funds we track also report a position in JANX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$171.9M), Prosight Management, LP (US$58.4M), TCG Crossover Management, LLC (US$27.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JANX

All JANX fund holders →

FAQ

How long has Lion Point Capital, LP held JANX?

Lion Point Capital, LP has disclosed JANX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Lion Point Capital, LP's current position in JANX?

As of Q2 2026, Lion Point Capital, LP holds 19.00K shares of JANX (JANUX THERAPEUTICS INC), valued at $291.84K, representing 1.40% of its reported portfolio and ranking #26.

Has Lion Point Capital, LP been buying or selling JANX?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in JANX. The position peaked in Q2 2026 at 19.00K shares.

Which other funds hold JANX?

Other major institutional holders of JANX include RA CAPITAL MANAGEMENT, L.P., Prosight Management, LP, TCG Crossover Management, LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.